A Physiologically Based Modeling Approach to Evaluate Intravenous Levetiracetam Dosing in Term and Preterm Neonates.

ABSTRACT: Seizures are the most common neurologic emergency in neonates and are associated with significant morbidity and mortality. Current first-line pharmacotherapy, phenobarbital, is associated with serious adverse effects, including impairment of the developing brain. Levetiracetam is a well-tolerated alternative; however, its use is limited because its optimal dosing in neonates remains unknown. Additionally, limited knowledge of levetiracetam pharmacokinetics in neonates, especially preterm neonates, means they generally receive the same weight-based dosing. This may put preterm neonates at risk of increased adverse events or insufficient drug effects. This study developed a physiologically based pharmacokinetic (PBPK) model for levetiracetam in term and preterm neonates to evaluate their pha

SUBMITTER: Johnson A 

PROVIDER: S-EPMC12484410 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature